In the era before Janus kinase (JAK) inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown. Our analyses suggest that initiation of JAK inhibitors nullifies the negative prognostic implication of unfavorable cytogenetics established in the preeJAK inhibitor therapy era. Introduction: In the era before Janus kinase (JAK) inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown. Patients and Methods: We performed a retrospective analysis of 180 patients with bone marrow biopsy eproven myelofibrosis from 3 US academic medical centers. We fit Cox proportional hazards models for overall survival and transformation-free survival on the bases of 3 factors: JAK inhibitor therapy as a time-dependent covariate, dichotomized cytogenetic status (favorable vs. unfavorable), and statistical interaction between the two. The median follow-up time was 37.1 months. Results: Among patients treated with best available therapy, unfavorable cytogenetic status was associated with decreased survival (hazard ratio ¼ 2.31; P ¼ .025). At initiation of JAK inhibitor therapy, unfavorable cytogenetics was (nonsignificantly) associated with increased survival compared to favorable cytogenetics (hazard ratio ¼ 0.292; P ¼ .172). The ratio of hazard ratios was 0.126 (P ¼ .034). These findings were similar after adjusting for standard clinical prognostic factors as well as when measured against transformation-free survival. Conclusion: The initiation of JAK inhibitor therapy appears to change the association between cytogenetics and overall survival. There was little difference in survival between treatment types in patients with favorable cytogenetics. However, the use of JAK inhibitor therapy among patients with unfavorable cytogenetics was not associated with worse survival compared to favorable cytogenetics. Our analyses suggest that initiation of JAK inhibitor therapy nullifies the negative prognostic implication of unfavorable cytogenetics established in the preeJAK inhibitor therapy era.
Introduction
Myelofibrosis (MF) is an acquired clonal Philadelphia chromosomeenegative myeloproliferative neoplasm that is characterized by progressive bone marrow fibrosis. 1 The disease can present as primary MF (PMF) or, after transformation from polycythemia vera (PV) and essential thrombocythemia (ET), as post-PV MF (PPV-MF) and post-ET MF (PET-MF), respectively. 2,3 PPV-MF and PET-MF are also known collectively as secondary MF (SMF). 2 The disease course of MF is complicated by progressive anemia, symptomatic splenomegaly, and severe constitutional symptoms.
development of prognostic scoring systems. The 2009 published International Prognostic Scoring System (IPSS) and the 2010 published dynamic IPSS (DIPSS) model were previously used for estimating survival in MF. 4, 6, 7 Both models estimated survival using risk factors including age, hemoglobin, leukocyte count, circulating blasts percentage, and presence of constitutional symptoms. 8, 9 The DIPSS-Plus model was developed in 2011 and was further refined with the addition of platelet count, transfusion dependency, and cytogenetics. This scoring system can assess prognosis at any time during follow-up. 4, 8 Cytogenetic abnormalities have served as prognostic factors in many myeloid malignancies including acute myeloid leukemia and myelodysplasia. 5, 10, 11 The prognostic value of cytogenetic findings in MF has long been suggested, and several studies show that cytogenetic abnormalities have closely predicted survival in MF patients. 12, 13 Cytogenetic profiles have historically been classified as either favorable or unfavorable on the basis of survival outcomes. 4, 8 In addition, the detrimental effect of unfavorable cytogenetics on leukemia-free survival has also been implied. 14 Historically, therapeutic options for MF patients consisted of cytoreductive agents (ie, hydroxyurea), splenectomy and splenic irradiation, transfusions for management of anemia, erythropoiesisstimulating agents, androgens, and immunomodulatory agents. 15 Only recently in 2011 has ruxolitinib, an inhibitor of Janus kinase (JAK) 1/2, been approved by the US Food and Drug Administration (FDA) for the treatment of intermediate-to highrisk MF patients. 16, 17 JAK inhibitors have become the mainstay of treatment for symptomatic MF patients and have been shown to improve quality of life and reduce spleen size. 18, 19 The phase 3
COMFORT-I and COMFORT-II trials have suggested a survival benefit with ruxolitinib compared to placebo or best available therapy (BAT). 17, 18, [20] [21] [22] [23] The currently used prognostic model, DIPSS-Plus, predicts survival in MF on the basis of clinical, laboratory, and cytogenetic information. However, its value in predicting clinical response or survival during treatment with JAK inhibitors remains relatively unknown. 8 The purpose of this study was to determine if the use of JAK inhibitors changes the association between cytogenetics and prognosis, as measured by OS and transformation-free survival (TFS).
Patients and Methods

Study Population
We performed a retrospective analysis on an initial cohort of 317 patients with bone marrow biopsyeproven MF, which included PMF, PPV-MF, and PET-MF, from the University of Michigan, Stanford University, and Mayo Clinic in Scottsdale, Arizona. Some data were collected and managed using the HemeCare database through REDCap hosted at the University of Michigan. 24 All patients were diagnosed with MF and treated between 1988 and 2016. Among these patients, 244 received an experimental or FDAapproved JAK inhibitor at some point during their disease course. Institutional review board approval was obtained for this study.
The criteria for the study population are described in the Supplemental Data in the online version. We excluded patients who likely switched to a JAK inhibitor as a result of prior treatment failure, which would confound the JAK inhibitor survival association. After applying these criteria to our cohort, 180 eligible patients remained. A total of 176 of 180 patients were diagnosed with MF or treated in 2004 or later. Among these, 73 patients were only treated with BAT over the course of their follow-up. BAT included any commercially available agent (monotherapy or combination therapy) or no therapy at all. These available agents included antineoplastic agents (ie, hydroxyurea), glucocorticoids, immunomodulatory agents (ie, thalidomide and lenalidomide), pyrimidine analogs (cytarabine), and/or antigonadotropins (danazol). Among the 107 patients treated a JAK inhibitor, 74 (69%) were treated with ruxolitinib (Jakafi, INCB018424). The remaining were treated with an experimental JAK inhibitor, including 17 (16%) with momelotinib (CYT387), 9 (8%) with fedratinib (SAR302503, TG101348), 4 (4%) with gandotinib (LY2784544), 1 (1%) with NS-018, 1 (1%) with itacitinib (INCB039110), and 1 (1%) with XL019.
Cytogenetics
All cytogenetic testing was performed on bone marrow aspirates at initial diagnosis. Chromosomal abnormalities were considered clonal if the same structural abnormality appeared in at least 3 metaphases. Patients were stratified using a 2-tiered cytogenetic risk categorization, unfavorable and favorable, based on Caramazza et al. 4 Unfavorable cytogenetics included complex karyotype (! 3 rearrangement abnormalities), or one or two abnormalities that included trisomy 8; deletion 7/7q; inversion 17q; inversion 3; deletion 5/5q; deletion 12p; or 11q23 rearrangement. All other scenarios, including normal karyotype, were considered favorable.
Survival Outcomes
The primary outcome was OS measured from time of diagnosis, and the secondary outcome was TFS (ie, the minimum time to We also considered multivariable survival analyses adjusting for patient-level baseline (ie, time of diagnosis) characteristics of age, sex, hemoglobin, white blood cell count (WBC), platelet count, peripheral blast count, fibrosis grade, and transfusion dependence. This set includes all components of existing prognostic scoring systems (eg, IPSS, DIPSS, DIPSS-Plus) except for the presence of constitutional symptoms, which was not reported in our data. These additional prognostic factors were incorporated using backward variable selection. Missing data in the prognostic covariates was accounted for using multiple imputation.
All statistical analyses were conducted in the R statistical environment. [25] [26] [27] Further statistical details are provided in the Supplemental Data in the online version. 
Results
The presenting cytogenetic categories and distribution are outlined in Table 1 . The baseline characteristics of the MF patients enrolled onto this study are summarized in Table 2 and compare those who were treated exclusively with BAT and those who received a JAK inhibitor. IPSS scores were calculated because FDA approval for JAK inhibitor use in intermediate-2 and high-risk MF patients utilized this model.
The median time from diagnosis to last follow-up with a care provider or death in the survival cohort (n ¼ 180) was 37.1 months. The potential median follow-up time using the reverse KaplanMeier method 29 was 56.7 months. The reverse Kaplan-Meier method is a statistical technique to estimate what the distribution of follow-up times would have been in the absence of any deaths. Among patients who received JAK inhibitor therapy, the median time from initiation of therapy to last follow-up or death was 27.3 months. Among all 166 patients in the analysis cohort with recorded cytogenetics, the Kaplan-Meier estimated median time to death from diagnosis was 62 and 46 months for favorable and unfavorable groups, respectively (P ¼ .438; Figure 1 ). In the subset of 73 patients who only received BAT, these median times decreased to 58 and 26 months, respectively (P ¼ .025; Figure 2 ). Among the 93 patients receiving JAK inhibitor therapy, the median time to death from initiation of therapy was 91 months for the favorable group and was not reached for the unfavorable group (P ¼ .183; Supplemental Figure 1 in the online version). When adjusting for cytogenetics on a univariable basis, unfavorable cytogenetic status was slightly associated with increased mortality (HR ¼ 1.24; P ¼ .53; Table 3 ). The initiation of JAK inhibitor therapy was univariably associated with reduced mortality, again not significantly (HR ¼ 0.772; P ¼ .27; second row). When jointly analyzing cytogenetic status, treatment type, and corresponding interactions, significant associations with survival were observed. Here we focus on this model. Among BAT patients, having unfavorable cytogenetics increased mortality relative to favorable cytogenetic status (HR ¼ 2.31; P ¼ .025). The statistical interaction between JAK inhibitor therapy and cytogenetic status was significantly less than 1 (HR ¼ 0.126, P ¼ .03), which implies that patients with unfavorable cytogenetics who were treated with a JAK inhibitor experienced decreased mortality relative to patients with favorable cytogenetics treated with a JAK inhibitor (HR, [2.31 Â 0.126] ¼ 0.292). Among patients with favorable cytogenetics, JAK inhibitor therapy was associated with a similar rate of mortality as BAT (HR ¼ 0.950; P ¼ .84). Figure 3 visualizes the fitted model in terms of predicted survival when JAK inhibitor therapy begins immediately at diagnosis. The model predicts no significant difference in survival between treatments when cytogenetic status is favorable (HRs 1 [reference group] and 0.950, respectively, for BAT and JAK inhibitor therapy; Figure 3 , left). However, significant survival differences are seen between treatments when cytogenetic status is unfavorable (HRs 2.31 and [2.31 Â 0.126 Â 0.950] ¼ 0.278, respectively, for BAT and JAK inhibitor therapy; Figure 3 , right). To summarize, the multivariable model suggests that survival differs between treatments only when cytogenetic status is unfavorable.
Our model-building procedure selected age, high WBC, low platelets, hemoglobin, and peripheral blasts ! 1% as relevant prognostic variables. Importantly, our main findings remained unchanged after adjusting for these confounders: the adjusted HR for the statistical interaction was 0.121 (P ¼ .03). We saw similar results when modeling TFS: unfavorable cytogenetic status was associated with shorter TFS among patients never receiving JAK inhibitor therapy (HR ¼ 2.00; P ¼ .077; Table 3 ), but this decreased by a factor of nearly 4 in the presence of JAK inhibitor therapy (HR ¼ 0.262; P ¼ .079).
Discussion and Conclusion
In this study, we performed a retrospective long-term patient follow-up of MF patients by assessing the effect of cytogenetics on the primary end point of OS. Our analyses suggest that initiation of JAK inhibitors nullifies the negative prognostic implication of unfavorable cytogenetics established in the preeJAK inhibitor era. In the absence of a concurrent randomized control group, we constructed an historical cohort of patients as a control for the survival analysis. An OS benefit was observed for patients with favorable (vs. unfavorable) cytogenetics treated with BAT, consistent with the results of studies in the era before JAK inhibitor therapies and during the time when the DIPSS-Plus model was created. 4 The initiation of JAK inhibitor therapy appears to change the association between cytogenetics and OS. In fact, we observed that among patients treated with JAK inhibitors, those with unfavorable cytogenetics did not have worse survival outcomes compared to those with favorable cytogenetics. Importantly, these findings remained consistent after adjusting for 
Figure 3 Visualization of Fitted Model for Predicted Survival for BAT and JAK Inhibitor Therapy
Abbreviations: BAT ¼ best available therapy; JAK ¼ Janus kinase.
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Clinical Lymphoma, Myeloma & Leukemia May 2018 -e205 DIPSS-Pluserelated factors, including age, high WBC, low platelet count, hemoglobin, and percentage peripheral blasts. The results were similar for the secondary outcome of TFS (Supplemental Figure 2 in the online version). We also considered the association between cytogenetics and splenic response to the initiation of JAK inhibitor therapy. Spleen reduction was used as a surrogate for response to therapy, as prior studies have correlated survival in JAK inhibitoretreated patients with the degree of spleen size reduction. 20, 30 We analyzed patients in the original cohort and created a logistic regression model for predicting the probability of 3-or 6-month splenic response as a function of cytogenetic status as well as initial spleen size at time of JAK inhibitor initiation. Details of the analysis and results are summarized in the Supplement Data and Supplemental Table 1 in the online version. In contrast to our survival models, unfavorable cytogenetic status was associated with a decreased probability of splenic response at 3 and 6 months from initiation of JAK inhibitor therapy despite significantly longer OS. Currently, the exact mechanisms by which JAK inhibitors prolong survival and ameliorate splenomegaly remain unclear, but they may be independent factors. Ruxolitinib has been associated with reductions in both inflammatory cytokines and markers of inflammation, likely leading to spleen size reduction. 21 JAK inhibitoretreated patients also experience metabolic improvement and weight gain, suggesting that alleviation of cachexia may be the mechanism underlying prolonged survival. Because our analysis of therapy response is limited only to patients who received JAK inhibitors, we are unable to test for a true statistical interaction as in the survival models.
Ideally, a prospective randomized clinical trial stratified by cytogenetic status would be equipped to fit such a model with interactions. Although the phase 3 COMFORT studies included only intermediate-2 or high-risk MF patients, data from nonrandomized studies have confirmed the benefits, particularly spleen reduction and symptom improvement, with ruxolitinib in intermediate-1 risk groups. 31 Thus, our analysis included patients with intermediate-1
risk MF who may have been treated with a JAK inhibitor. On a univariable basis, we noted a positive but nonsignificant association between OS and JAK inhibitor therapy, which is consistent with prior studies demonstrating modest survival benefits with ruxolitinib. A reanalysis of the COMFORT-II trials at 3 years failed to note a statistically significant difference in survival between the ruxolitinib and placebo groups, even after accounting for crossover from the BAT arm to the ruxolitinib arm. 18 We are mindful that our study cohort differed from COMFORT-II in the populations analyzed, the array of different JAK inhibitors used, and the statistical modeling used in our study cohort. One of the aims of cytogenetic risk stratification is to define a high-risk group versus a standard risk group. 8 The DIPSS-Plus model has classified several karyotype abnormalities as unfavorable (complex karyotype or one or two abnormalities including þ8, À7/ 7q, i(17q), À5/5qÀ, 12pÀ, inv(3), or 11q23 rearrangement) on the basis of poorer survival outcomes. 8 However, the prevalence of unfavorable cytogenetics in MF patients is rare. Thus, the inherent selection bias associated with unfavorable cytogenetics may confound studies attempting to categorize favorable and unfavorable cytogenetics. Currently, there is no consensus on the prognostic stratification of cytogenetics favorability across all subtypes of MF. A larger number of study patients with cytogenetic abnormalities is needed to resolve these issues. Our current study includes patients with SMF, which encompasses post-ET MF and post-PV MF. Of note, the DIPSS-Plus scoring system has only been validated for patients with PMF. Given that treatment modalities for PMF are similar for PPV-MF and PET-MF, the current scoring system is often used for patients with SMF despite potential inaccuracies from extrapolation to these populations. 24 Efforts to develop new prognostic models for PMF and SMF are ongoing. Most notably, a multicenter-based model, the MYSEC prognostic model, was recently developed to predict survival for SMF without the use of cytogenetics information. 32 Cytogenetic information was excluded from analysis because only a minority of their study cohort underwent cytogenetic testing. A more recently published study unveiled two prognostic systems, called the MIPSS70 and MIPSS70-plus, which provides risk stratification for transplantation-age patients with PMF. 33 Two independent cohorts were analyzed leading to the creation of their respective models. However, only the MIPSS70-plus model utilized cytogenetic information because its cohort had a sufficient number of patients with cytogenetic information. In general, the utility of cytogenetic information in prognostic modeling has often been limited by the prevalence of which cytogenetic testing is performed.
Although we examined the impact of cytogenetics on survival and response to JAK inhibitor therapy, the relationship between cytogenetics and JAK mutation is not yet clear. While cytogenetic abnormalities exist in many patients, no consistent genetic marker or genetic signature has been identified. 34 JAK inhibitors have elicited response in MF patients, irrespective of JAK mutation status. 35 The clinical efficacy of these drugs may suggest broader inhibition and effects beyond the JAK/STAT signaling pathway. Future work will be required to elucidate the mechanism by which JAK inhibitors are efficacious and to elucidate if any related disease markers or patient characteristics, besides cytogenetics, could be helpful in identifying which patients may benefit most from JAK inhibitor therapy. 35, 36 Our study has several limitations, including its retrospective nature. We constructed our survival model using historical controls, which can introduce selection bias and time bias, but efforts were made to reduce these by developing strict exclusion criteria. Second, several patients did not have cytogenetic testing performed at initial diagnosis. This may be due to inaccessible records or lack of commercially available cytogenetic testing at the time of diagnosis; however, our analysis used multiple imputation methods to account for the missing data. Third, our cohort did not include information on somatic mutations, which can have prognostic relevance. 37 At this time, patients with MF are living longer while receiving the current standard therapy, including JAK inhibitors, although we cannot definitively presume an OS benefit without a randomized controlled study. To address some of these questions, the findings of the current study should be the basis of a future prospective evaluation to expand our cohort analysis.
Clinical Practice Points
In the era before JAK inhibitors, cytogenetic information was used to predict survival in MF patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown.
In an attempt to change the perspective on how we prognosticate the disease course and treatment of MF patients, we performed analyses that suggested that initiation of JAK inhibitors nullifies the negative prognostic implication of unfavorable cytogenetics established in the era before JAK inhibitor therapy. As such, the current use of unfavorable cytogenetics as a prognostic parameter in the DIPSS-Plus model is archaic in the setting of JAK inhibitor use. Cytogenetic favorability will need to be redefined as we develop novel therapies to treat MF. Our study creates a paradigm for future studies to elucidate other prognostic factors that could be helpful in identifying which patients may benefit most from JAK inhibitor therapy.
Supplemental Data
Study Population Criteria
The time from diagnosis to commencement of JAK (Janus kinase) inhibitor therapy was highly variable. The middle quartiles for time to JAK inhibitor therapy were 5, 17, and 35 months. Thirty-three patients had time to JAK inhibitor therapy initiation of at least 5 years. Many of these patients were diagnosed before US Food and Drug Administration (FDA) approval of ruxolitinib in November 2011 and initiated JAK inhibitor therapy after FDA approval. For these patients, treatment failure of BAT was likely the reason for switching to JAK inhibitor therapy and was therefore likely to be a surrogate for clinical outcome. Thus, we constructed eligibility criteria for our initial cohort of 317 patients to exclude those with this potential surrogacy relationship. Patients in the original cohort were included in the analysis cohort only if one of the following criteria was satisfied: 
Splenic Response Analysis
We also considered the association between cytogenetics and splenic response from the initiation of JAK inhibitor therapy using a logistic regression. We used a slightly modified International Working GroupeMyeloproliferative Neoplasms Research and Treatment criteria, at approximately 3 months and 6 months from initiating a JAK inhibitor, as previously described. 38 Response was defined by a ! 50% reduction in spleen size. Our modification permitted evaluation of those with baseline splenomegaly palpable < 5 cm, and if the spleen became impalpable, these patients were classified as having disease that responded to therapy. A patient was deemed to have an end point if they had one splenic examination or imaging size recording within a period of around 3 or 6 months. Data on splenic response from initiation of JAK inhibitor therapy were limited to those patients who received JAK inhibitor therapy. Further, splenic response at 3 months was available only in 172 of the 244 JAK inhibitor patients, and in 160 patients at 6 months. We fit logistic regression models for predicting the probability of 3-or 6-month splenic response as a function of cytogenetic status as well as initial spleen size at time of JAK inhibitor initiation, grouped into 5 categories (< 5 cm, 5-10, 10-15, 15-20, > 20 cm).
Coding Scheme for Prognostic Variables
In addition to cytogenetic status and JAK inhibitor therapy status, we evaluated a total of 8 additional prognostic variables for inclusion in the multivariable model. Four were modeled as categorical: sex (M/F), European Consensus Grade (MF-1, MF-2, or MF-3; transformed into 2 dummy indicator variables), transfusion dependence (yes/no), and percentage of peripheral blasts ! 0 (yes/no). The remaining 4 were continuous age (years), hemoglobin (g/dL), white blood cell count (WBC) (10 9 /L), and platelet count (10 9 /L). Hemoglobin was log 2 transformed.
We modeled the associations between WBC and survival to account for potentially changing risk profiles among patients with leukopenia and leukocytosis. Specifically, we constructed a mixed discrete-continuous variable exactly as described in the supplemental data of our previous study: 38 We first mapped each WBC count into a three-category vector, based upon whether it was below 5, between 5 and 10, or greater than 10. The numeric value of the middle category was always zero and used as a reference. The numeric value of the extreme categories was only nonzero if the count fell in that category. In that case, we calculated the absolute value of the log2-ratio of the count and the boundary value (either 5 or 10). So, for example, a WBC count of 4*10 9 /L was mapped to the vector (0.322, 0, 0), because log2(5/4) ¼ 0.322, whereas a WBC count of 12 was mapped to (0, 0, 0.263), because log2(12/10) ¼ 0.263. We transformed platelet counts similarly, using 150 and 450 as normal boundaries.
Missing Data
We used the partial information from observations with missing data by using multiple imputation with chained equations. 39 We imputed 50 data sets. We stacked the completed data sets and fit each statistical model using the entire stacked data set, so that each patient's data appeared a total of 50 times. To properly estimate the variance of parameter estimates in the presence of this stacked data set, we weighted each observation's likelihood contribution by 1/50. In this way, we were able to properly account for imputation uncertainty in our statistical models.Data Profile 
